{
    "clinical_study": {
        "@rank": "14932", 
        "arm_group": [
            {
                "arm_group_label": "H.pylori eradication", 
                "arm_group_type": "Experimental", 
                "description": "H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity."
            }, 
            {
                "arm_group_label": "Lifestyle modification", 
                "arm_group_type": "No Intervention", 
                "description": "Obtaining ideal body weight by calorie restriction diet and programmed physical activity"
            }
        ], 
        "brief_summary": {
            "textblock": "The role of Helicobacter pylori(HP)in the pathogenesis of non-alcoholic fatty liver disease\n      (NAFLD) is controversial."
        }, 
        "brief_title": "The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Fatty Liver", 
            "Liver Dysfunction", 
            "Insulin Resistance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatty Liver", 
                "Insulin Resistance", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This randomized double blind clinical trial was performed in dyspeptic patients with\n      positive antibody to HP and the evidence of fatty liver in ultrasonography. After excluding\n      other causes, participants with persistent elevated serum aminotransferase levels were\n      presumed to have NAFLD. Those with NAFLD liver fat score greater than (-0.64) and positive\n      urea breath test (UBT) were enrolled. They were randomly assigned to lifestyle modification\n      alone or lifestyle modification plus HP eradication groups. Quadruple therapy (omeprazole,\n      amoxicillin, bismuth subcitrate, and clarithromycin) for HP eradication was performed in two\n      weeks. HP eradication was documented by UBT. Liver fat content, fasting serum glucose,\n      alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride,\n      cholesterol, high and low-density lipoprotein,homeostasis model assessment-insulin\n      resistance(HOMA-IR), and anthropometric measurements (body mass index and waist\n      circumference) were checked at baseline and six months later."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  dyspeptic patients with positive antibody to H.pylori and\n\n          -  persistent elevated aminotransferase levels with the evidence of fatty liver in\n             ultrasonography, who were referred to a gastroenterology clinic.\n\n        Exclusion Criteria:\n\n          -  alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),\n\n          -  heart disease (ischemic or congestive),\n\n          -  hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease,\n             hemochromatosis, liver mass lesion),\n\n          -  renal disease (serum creatinine concentration of > 1.5 mg/dl),\n\n          -  any severe systemic co-morbidities, neoplasm,\n\n          -  using any hepatotoxic medication during the past 3 months,\n\n          -  previous history of peptic ulcer,\n\n          -  previous history of H.pylori eradication,\n\n          -  existence of alarm signs (weight loss, dysphagia, anemia, vomiting, positive family\n             history of gastrointestinal cancers), and\n\n          -  pregnant or lactating women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876108", 
            "org_study_id": "1392/3/11- 589"
        }, 
        "intervention": {
            "arm_group_label": "H.pylori eradication", 
            "description": "The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.", 
            "intervention_name": "H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)", 
            "intervention_type": "Drug", 
            "other_name": "H.pylori treatment"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Azithromycin", 
                "Bismuth tripotassium dicitrate", 
                "Bismuth", 
                "Omeprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Steatohepatitis", 
            "Helicobacter pylori", 
            "Alanine aminotransferase", 
            "Aspartate aminotransferase", 
            "Fatty Liver", 
            "Liver Diseases", 
            "Digestive System Diseases"
        ], 
        "lastchanged_date": "July 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Gastroenterology clinic, Sina Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-alcoholic Fatty Liver Disease", 
        "other_outcome": {
            "measure": "Change from baseline insulin resistance at 6 months", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "overall_official": {
            "affiliation": "Tehran University of Medical Sciences", 
            "last_name": "Raika Jamali, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline liver fat content at 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876108"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tehran University of Medical Sciences", 
            "investigator_full_name": "Raika Jamali, MD", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change from baseline liver function tests at 6 months", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Tehran University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tehran University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}